Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

High incidence of secondary hypertension in patients referred for renal denervation--the Copenhagen experience

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{6976a5b2073f427ea5cb125282e9f5c6,
title = "High incidence of secondary hypertension in patients referred for renal denervation--the Copenhagen experience",
abstract = "Percutaneous renal denervation is a new treatment option for patients with resistant hypertension and little is known about the eligibility of patients referred. 100 consecutive patients were referred for renal denervation from March 2011 through September 2012. Clinical data were prospectively extracted from letters and documents from referring clinics and from our physical examination. Of the 100 patients included, 68 were men and the mean age was 60 (± 12) years. Office blood pressure was 176 (± 28)/99 (± 19) mmHg and 24-h ambulatory blood pressure 156 (± 20)/88 (± 13) mmHg. The mean number of antihypertensive agents was 4.0 (± 1.6). Nearly four-fifths (82{\%}) of the patients were categorized as having resistant hypertension based on the criteria stated by The American Heart Association's stated criteria. Nine patients declined interest in renal denervation before completing the clinical workup program. Thus, 91 patients were screened, and of those 51 were found to be candidates for renal denervation. Forty patients were not candidates, of which secondary hypertension was the most common cause (n = 10). Only 51{\%} of patients referred for renal denervation were eligible for treatment. The prevalence of secondary hypertension was 10{\%} of the referred population. Secondary hypertension should therefore be considered in the evaluation of candidates for renal denervation.",
author = "Olsen, {Lene Kj{\ae}r} and Anne-Lise Kamper and Svendsen, {Jesper Hastrup} and Bang, {Lia Evi} and Marie Frimodt-M{\o}ller and Henning Kelb{\ae}k and Mikael Sander and Bo Feldt-Rasmussen",
year = "2014",
month = "8",
doi = "10.3109/08037051.2013.867655",
language = "English",
volume = "23",
pages = "233--9",
journal = "Blood Pressure",
issn = "0803-7051",
publisher = "Informa Healthcare",
number = "4",

}

RIS

TY - JOUR

T1 - High incidence of secondary hypertension in patients referred for renal denervation--the Copenhagen experience

AU - Olsen, Lene Kjær

AU - Kamper, Anne-Lise

AU - Svendsen, Jesper Hastrup

AU - Bang, Lia Evi

AU - Frimodt-Møller, Marie

AU - Kelbæk, Henning

AU - Sander, Mikael

AU - Feldt-Rasmussen, Bo

PY - 2014/8

Y1 - 2014/8

N2 - Percutaneous renal denervation is a new treatment option for patients with resistant hypertension and little is known about the eligibility of patients referred. 100 consecutive patients were referred for renal denervation from March 2011 through September 2012. Clinical data were prospectively extracted from letters and documents from referring clinics and from our physical examination. Of the 100 patients included, 68 were men and the mean age was 60 (± 12) years. Office blood pressure was 176 (± 28)/99 (± 19) mmHg and 24-h ambulatory blood pressure 156 (± 20)/88 (± 13) mmHg. The mean number of antihypertensive agents was 4.0 (± 1.6). Nearly four-fifths (82%) of the patients were categorized as having resistant hypertension based on the criteria stated by The American Heart Association's stated criteria. Nine patients declined interest in renal denervation before completing the clinical workup program. Thus, 91 patients were screened, and of those 51 were found to be candidates for renal denervation. Forty patients were not candidates, of which secondary hypertension was the most common cause (n = 10). Only 51% of patients referred for renal denervation were eligible for treatment. The prevalence of secondary hypertension was 10% of the referred population. Secondary hypertension should therefore be considered in the evaluation of candidates for renal denervation.

AB - Percutaneous renal denervation is a new treatment option for patients with resistant hypertension and little is known about the eligibility of patients referred. 100 consecutive patients were referred for renal denervation from March 2011 through September 2012. Clinical data were prospectively extracted from letters and documents from referring clinics and from our physical examination. Of the 100 patients included, 68 were men and the mean age was 60 (± 12) years. Office blood pressure was 176 (± 28)/99 (± 19) mmHg and 24-h ambulatory blood pressure 156 (± 20)/88 (± 13) mmHg. The mean number of antihypertensive agents was 4.0 (± 1.6). Nearly four-fifths (82%) of the patients were categorized as having resistant hypertension based on the criteria stated by The American Heart Association's stated criteria. Nine patients declined interest in renal denervation before completing the clinical workup program. Thus, 91 patients were screened, and of those 51 were found to be candidates for renal denervation. Forty patients were not candidates, of which secondary hypertension was the most common cause (n = 10). Only 51% of patients referred for renal denervation were eligible for treatment. The prevalence of secondary hypertension was 10% of the referred population. Secondary hypertension should therefore be considered in the evaluation of candidates for renal denervation.

U2 - 10.3109/08037051.2013.867655

DO - 10.3109/08037051.2013.867655

M3 - Journal article

VL - 23

SP - 233

EP - 239

JO - Blood Pressure

JF - Blood Pressure

SN - 0803-7051

IS - 4

ER -

ID: 44873723